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In mammalian cells, mRNA decay begins with deadenylation, which involves two consecutive phases medi-
ated by the PAN2-PAN3 and the CCR4-CAF1 complexes, respectively. The regulation of the critical deadenyl-
ation step and its relationship with RNA-processing bodies (P-bodies), which are thought to be a site where
poly(A)-shortened mRNAs get degraded, are poorly understood. Using the Tet-Off transcriptional pulsing
approach to investigate mRNA decay in mouse NIH 3T3 fibroblasts, we found that TOB, an antiproliferative
transcription factor, enhances mRNA deadenylation in vivo. Results from glutathione S-transferase pull-down
and coimmunoprecipitation experiments indicate that TOB can simultaneously interact with the poly(A)
nuclease complex CCR4-CAF1 and the cytoplasmic poly(A)-binding protein, PABPC1. Combining these find-
ings with those from mutagenesis studies, we further identified the protein motifs on TOB and PABPC1 that
are necessary for their interaction and found that interaction with PABPC1 is necessary for TOB’s deadenyl-
ation-enhancing effect. Moreover, our immunofluorescence microscopy results revealed that TOB colocalizes
with P-bodies, suggesting a role of TOB in linking deadenylation to the P-bodies. Our findings reveal a new
mechanism by which the fate of mammalian mRNA is modulated at the deadenylation step by a protein that
recruits poly(A) nuclease(s) to the 3 poly(A) tail-PABP complex.
Deadenylation is the first major step that triggers mRNA
decay in eukaryotic cells (reviewed in references 19, 41, and
44). Computational modeling of eukaryotic mRNA turnover
indicates that changes in levels of mRNA are highly leveraged
to the rate of deadenylation (8). The importance of deadenyl-
ation in regulating mammalian mRNA turnover can be ob-
served in several modes of mRNA decay, including decay di-
rected by AU-rich elements in the 3 untranslated region (4,
10), the rapid decay mediated by destabilizing elements in
protein-coding regions (9, 23), the surveillance mechanism that
detects and degrades nonsense-containing mRNA (11), and
the decay directed by microRNA (59). Shortening of the 3
poly(A) tail also plays a critical role in rendering mRNAs
nontranslatable (26, 46, 58), thus inactivating gene expression.
In spite of the importance of deadenylation, relatively little is
known about the mechanisms that control it.
Recent progress in identifying key mammalian poly(A)
nucleases involved in deadenylation (1, 6, 13, 16, 20, 38, 53, 55)
has offered the opportunity to examine the regulation of de-
adenylation and to characterize the participating regulatory
proteins. In mammalian cells, shortening of the poly(A) tail is
mediated by the consecutive activities of two different poly(A)
nuclease complexes (61). During the first phase, PAN2, pre-
sumably complexed with PAN3 (53, 61), shortens the poly(A)
tails to 110 A nucleotides. In the second phase, CCR4, pre-
sumably complexed with CAF1 (6, 55, 61), further shortens the
poly(A) tail to oligo(A). Decapping mediated by the DCP1-
DCP2 complex (36, 54, 56) was found to occur after either the
first or the second phase of deadenylation (61).
To identify the potential regulatory factors involved in mam-
malian deadenylation, we have carried out literature and da-
tabase searches with a focus on proteins that have the potential
to interact with a poly(A) nuclease and/or the cytoplasmic
poly(A)-binding protein (PABPC1). A family of antiprolifera-
tive genes, termed the tob/btg family (reviewed in references 24
and 39), emerged from the searches, because they contain a
highly conserved N-terminal domain that can interact with
CAF1 (7, 42). In humans, this family consists of six members:
tob, tob2, ana, pc3b, btg1, and btg2, among which tob and tob2
also encode a C-terminal domain with two putative PABP-
interacting motifs (24, 39). Increasing evidence suggests that
TOB proteins are involved in negative control of cell growth
and can function as tumor suppressors (25, 49, 62). Moreover,
TOB is highly expressed in anergic T-cell clones and in un-
stimulated peripheral blood T lymphocytes (52). The ability of
TOB to maintain T-cell quiescence is thought to be due to its
modulation of transcription (52). Despite the fact that TOB
proteins have been known for a decade to function in antipro-
liferation and potentially in transcriptional control, the bio-
chemical and molecular mechanisms by which they exert their
functions remains unclear.
In this study, our results revealed that TOB proteins mod-
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ulate deadenylation, a key step in mRNA turnover. In addi-
tion, TOB protein localizes to RNA processing bodies (P-
bodies), cytoplasmic foci that are enriched in 5-to-3 decay
factors and translationally repressed mRNPs (for a recent re-
view, see reference 17). These findings suggest a novel role for
TOB proteins in regulating cytoplasmic deadenylation and
identify a new mechanism by which the fate of mammalian
mRNA is controlled at the deadenylation step by a protein that
interacts with both poly(A) nuclease(s) and PABPC1 and has
the potential to direct poly(A)-shortened mRNA intermedi-
ates to P-bodies.
MATERIALS AND METHODS
Plasmids. Construction of plasmids pSV1/GAPDH (12), pTet BBB (60),
pTet BBB-PTC (11), HA-CCR4a (9), and pGST-PABP, pGST-PABP-2nd-C,
and pGST-PABP-RRM1 (28) has been described previously. The GFP-hDcp1
plasmid was a gift from B. Seraphin (54). When PCR techniques were employed
to amplify desired DNA fragments for cloning, PfuUltra DNA polymerase
(Stratagene) was used. DNA sequencing was performed to confirm all the de-
sired mutations and in-frame fusions. To construct pTOB-V5, a 1,035-bp
BamHI-XhoI fragment from an IMAGE clone (BC031406; ATCC), spanning
the TOB coding region, was inserted in frame into the BamHI and XhoI site of
pcDNA6/V5-His A (Invitrogen). To construct pTOB2-V5, a 1,032-bp cDNA
encoding TOB2 was PCR amplified from a KIAA1663 clone (Kazusa DNA
Research Institute, Japan) and inserted between the HindIII and XbaI sites of
pcDNA6/V5-His A (Invitrogen). To generate MBP-TOB2, a 1,035-bp cDNA
encoding the TOB2 open reading frame was PCR amplified from the KIAA1663
clone and inserted between the SnaBI and XhaI sites of pMal-Y (a gift from S.
Ohno). Point mutations PABPC1 (F), PABP-2nd-C (F), TOB (FF), and TOB2
(FF) were created at positions as described below in the text using the
QuikChange multisite-directed mutagenesis kit (Stratagene) according to the
manufacturer’s instructions with pGST-PBAP, pGST-PABP-2nd-C, pTOB-V5,
and pTOB2-V5 as template.
Cell culture and transfection. Mammalian cell culture and DNA and small
interfering RNA transfections were carried out as described previously (61).
Briefly, NIH 3T3 B2A2 cells were split to a density of 0.6  106/6-cm dish 24 h
before transfection. A 2.4-g mixture of DNA (0.07 g of reporter plasmid, 0.07
g of internal control plasmid, 0.67 g of CCR4a plasmid, and 1.59 g of TOB
plasmids) was diluted into 0.4 ml of Dulbecco’s modified Eagle’s medium con-
taining 10% calf serum, into which 15 l of PolyFect (QIAGEN) was added and
mixed well. The mixture was then added to the culture dish. Time course
experiments using the Tet-Off system for transcriptional pulsing were performed
as described previously (35, 60).
Preparation of RNA samples and Northern blot analysis. Isolation of total
cytoplasmic RNA and Northern blot analysis were conducted as described pre-
viously (48). Briefly, total cytoplasmic mRNA was isolated at various time points
after the transcription pulse driven by the Tet-Off promoter of the reporter
plasmid in transfected cells. Gene-specific DNA probes were prepared by ran-
dom oligonucleotide priming for Northern blot analysis. A control plasmid en-
coding a 1.4-kb stable message, termed -globin/GAPDH, served as an internal
standard for normalization of the test messages. The 32P-labeled probes were
produced by inclusion of [-32P]dCTP (6,000 Ci/mmol; Perkin-Elmer). Data
were quantitated using a PhosphorImager (Bio-Rad). RNase H treatment of
cytoplasmic mRNA to generate poly(A) RNA and analysis of deadenylation
and decay curves were carried out as described previously (47). All experiments
were performed at least twice with reproducible results.
GST pull-down assay. Glutathione S-transferase (GST) pull-down assays were
performed using the MagneGST pull-down system (Promega) according to the
manufacturer’s instructions. Briefly, GST fusion proteins were expressed in Esch-
erichia coli BL21 (Amersham) and then induced by 0.5 mM isopropyl 	-D-
thiogalactoside at 30°C for 3 h. The cells were harvested and lysed in cell lysis
reagent containing protease inhibitor cocktail (Roche) and DNase (Promega).
The lysates were clarified by centrifugation at 14,000  g for 10 min. The
expressed GST fusion protein in the clear lysate was immobilized on MagneGST
particles (Promega) and then incubated with 5 l of the in vitro-translated
protein in 250 l of binding buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2
mM EDTA, 0.5% NP-40, and protease inhibitor cocktail). After incubation with
rotating for 1 h at 4°C, the MagneGST particles were washed four times with 400
l of radioimmunoprecipitation buffer (10 mM sodium phosphate, pH 7.2, 150
mM NaCl, 1% NP-40, and 0.5% sodium deoxycholate). The bound fraction was
eluted in 1 sodium dodecyl sulfate (SDS) loading buffer and analyzed by
SDS-polyacrylamide gel electrophoresis (SDS-PAGE). The gels were stained by
Coomassie blue to show equal loading of the GST fusion protein and then dried
for autoradiography to detect pull-down protein labeled with [35S]methionine.
For in vitro translation, [35S]methionine-labeled proteins were produced in the
rabbit reticulocyte lysate using an in vitro-coupled transcription/translation sys-
tem (Promega) in the presence of [35S]methionine (Amersham). The in vitro-
translated products were treated with DNase I (0.5 U/l) and RNase A (0.1
mg/ml) for 15 min at 30°C prior to being used in GST pull-down assays.
Gel mobility shift assay. GST-PABP-RRM1 (0.68 pmol) or GST-PABPC1
(0.25 pmol) was incubated with 0.5 pmol 32P-labeled poly(A)25 RNA probe (2 
103 cpm) with 0, 1.7, or 6.8 pmol of MBP-TOB2 for 15 min at room temperature
in 15 l of binding buffer (10 mM HEPES-KOH pH 7.6, 3 mM MgCl2, 100 mM
KCl, 5 mM EDTA, 2 mM dithiothreitol, 5% glycerol, 1.5 mg/ml heparin, 0.5%
NP-40, 0.2 mg/ml total yeast RNA). The mixtures were separated by electro-
phoresis on a 6% nondenaturing acrylamide gel (60:1 acrylamide-bisacrylamide)
in 0.5 Tris-borate-EDTA buffer. The 32P-labeled poly(A)25 RNA probe was
prepared as follows. A 10 M concentration of poly(A) (Dharmacon) was incu-
bated with 150 Ci ATP (6,000 Ci/mmol) and 30 U of T4 polynucleotide kinase
(New England BioLabs) at 37°C for 2 h. After phenol and chloroform extraction,
the probe was purified by using CHROMA SPIN columns (Clontech).
Coimmunoprecipitation and Western blot analysis. Cytoplasmic lysates were
prepared as described previously (45). Briefly, 48 h after transfection, COS7 cells
expressing wild-type or mutant TOB-V5 or TOB2-V5 or the control pcDNA6-V5
vector were harvested and lysed at 4°C in 600 l lysis buffer (20 mM Tris-HCl,
pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM Na-orthovanadate, 1 mM Na-pyrophos-
phate, and 1 mM NaF supplemented with a protease inhibitor cocktail [Roche]).
Fifty l of cell lysate was saved as “input” control, and the rest was incubated
with anti-V5 epitope antibody-conjugated agarose beads (Sigma) in the presence
of 0.1 mg/ml RNase A at 4°C for 4 h. The beads were subject to five washes with
the lysis buffer. The coprecipitated proteins were detected by Western blotting
with antibodies as indicated in the figures below. For Western blot analysis, the
protein samples were resolved on a 10% SDS-PAGE and transferred to an
Immobilon-P membrane (Millipore). For detecting ectopically expressed V5-
tagged or hemagglutinin (HA)-tagged proteins, membranes were incubated with
horseradish peroxidase (HRP)-conjugated monoclonal anti-V5 antibody
(1/5,000; Invitrogen) or HRP-conjugated monoclonal anti-HA antibody (1/1,000;
Roche), respectively. For detecting endogenous proteins, membranes were first
incubated with rabbit anti-CAF1-B peptide antibody (1/1,000), rabbit anti-
PAN2-B peptide (1/2,000), rabbit anti-PABP-N (1/4,000; R. Lloyd), or mouse
anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) monoclonal antibody
(1/10,000; Research Diagnostics). Secondary HRP-conjugated goat anti-rabbit im-
munoglobulin G antibodies (1/4,000; Bethyl) or goat anti-mouse antibodies (1/5,000;
Bio-Rad) were used for detection with chemiluminescence reagent (peroxide/lumi-
nol enhancer; Pierce).
Immunofluorescence microscopy. NIH 3T3 cells were transfected and pre-
pared for immunofluorescence microscopy as described previously (61), except
that various expression plasmids were delivered into NIH 3T3 cells by using
Fugene 6 reagent (Roche). To block translation elongation, cells were cultured
in medium containing 7.5 g/ml cycloheximide for 110 min. Mounting medium
containing 4,6-diamidino-2-phenylindole (DAPI) was applied to the slides for
visualization of cell nuclei. The slides were observed under a Delta Vision
deconvolution fluorescence microscope (X. He, Baylor College of Medicine). To
detect V5-tagged TOB proteins, the primary and secondary antibodies were
mouse antibody to V5 epitope tag (1:1,000 dilution; Invitrogen) and Alexa Fluor
555 goat anti-mouse antibody (1:1,000 dilution; Molecular Probes), respectively.
To detect endogenous CENP-F, rabbit primary antiserum against CENP-F (1:50;
Santa Cruz) and Alexa Fluor 647 chicken anti-rabbit antibody (1:1,000 dilution;
Molecular Probes) were used as primary and secondary antibodies, respectively.
For real-time imaging of P-bodies in live cells, 24 h after transfection with
GFP-hDcp1 plasmid, the NIH 3T3 cells were reseeded to a glass-bottom dish
(MatTek Corporation) in HEPES-buffered medium. After growing for another
22 h, the cells were observed under a Delta Vision deconvolution fluorescence
microscope at 37°C. Images of the transfected cells showing P-bodies were taken
every 5 min after addition or removal of cycloheximide.
RESULTS
TOB can interact simultaneously with PABPC1 and CCR4-
CAF1. Previously, we hypothesized that PABPC1 plays a crit-
ical role in deadenylation by modulating the activities of
PAN2-PAN3 and CCR4-CAF1 poly(A) nucleases in vivo (61).
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In the present study, we first performed GST pull-down exper-
iments to address whether PABPC1 directly interacts with
PAN2-PAN3 and CCR4-CAF1 poly(A) nucleases. Our results
(Fig. 1A) showed that PAN2, PAN3, and two positive controls
(PABPC1 itself and PABP-interacting protein 2 [Paip2]) can
be pulled down by GST-PABPC1. In contrast, a very modest
amount of CCR4 and no appreciable amount of CAF1 or
luciferase could be pulled down by GST-PABPC1.
As the CCR4-CAF1 complex is a major player in eukaryotic
deadenylation (5, 50, 51, 61), we then asked whether there
might be a PABP-interacting protein(s) that mediates the as-
sociation between this complex and the 3 poly(A) tail-PABP
complex, thus serving as a regulatory factor(s) in deadenyla-
tion. Database and literature searches drew our attention to
TOB, due to its ability to interact with CAF1, its potential to
bind PABPC1, and its critical role in regulation of gene ex-
pression (see the introduction). A direct interaction between
TOB protein and PABPC1 was confirmed by a GST pull-down
assay, and the interactions among TOB, CCR4, and CAF1
were also addressed (Fig. 1B). The presence of TOB led to an
appreciable pull-down of CAF1 and/or CCR4 by GST-
PABPC1 (Fig. 1B, lanes 3, 5, and 7), whereas no such pull-
down was detected in the absence of TOB (Fig. 1B, lanes 2, 4,
and 6). These data indicated that CCR4-CAF1 and PABPC1
interact at different sites on the TOB protein, allowing TOB to
associate with both of them simultaneously. These in vitro
findings suggest that TOB may regulate mRNA turnover by
modulating the deadenylation rate through a direct interaction
with poly(A) nucleases or by mediating the association be-
tween the CCR4-CAF1 complex and the 3 poly(A)/PABP
complex.
TOB can enhance deadenylation in vivo. To test whether
TOB can modulate deadenylation, we carried out transfection
experiments in NIH 3T3 cells and examined the effect of TOB
overexpression on deadenylation by monitoring decay of 	-glo-
bin mRNA (BBB) transcribed from the cotransfected plasmid
pTet-BBB under control of the Tet-Off-driven promoter (35,
60). As shown in Fig. 2A, overexpression of TOB (Fig. 2A,
middle panel) resulted in accelerated deadenylation of BBB
message accompanied by the appearance before the 1-h time
point of an intermediate bearing an oligo(A) tail, which did not
appear until the 8-h time point in control cells (Fig. 2A, left
panel). These findings indicated an earlier commencement of
the second phase of deadenylation in cells overexpressing
TOB. The poly(A)-shortening profile of the BBB mRNA for
each Northern blot assay was also graphed to illustrate how the
deadenylation kinetics were affected by TOB (see Fig. S1A,
left, in the supplemental material). The data showed that over-
expression of TOB caused a shift of the deadenylation curve
towards the position of the cognate poly(A) RNA and, again,
that a significant amount of the oligo(A)-containing interme-
diate appeared before the 1-h time point when TOB was over-
expressed.
Previously, we have shown that CCR4 plays a key role in the
second phase of deadenylation, when mRNAs with poly(A)
tails of 110 nucleotides are further shortened to oligo(A)
(61). The observations that TOB can interact with CCR4 and
CAF1 (Fig. 1B) and that overexpression of TOB enhances the
second phase of deadenylation (Fig. 2A; see also Fig. S1 in the
supplemental material) prompted us to ask whether coexpres-
sion of TOB and CCR4 would further speed up deadenylation.
Figure 2B shows that overexpression of CCR4 enhanced the
second phase of deadenylation of BBB mRNA (left panel).
Deadenylation was even more rapid when TOB and CCR4
were coexpressed (Fig. 2B, middle panel), compared with ex-
pression of CCR4 alone. Note that to better evaluate the fast
deadenylation kinetics, a 0.5-h time point was included and the
8-h time point was omitted for this set of experiments. The
nonsynchronous pattern and the presence of an oligo(A)-
mRNA intermediate were evident before the 0.5-h time point
(Fig. 2B, middle panel). Deadenylation profiles (see Fig. S1B,
left, in the supplemental material) for the Northern blot assays
also illustrate that the deadenylation of BBB mRNA was fur-
ther accelerated in the presence of TOB. Given that the level
of CCR4 expression was much lower when coexpressed with
TOB than when expressed alone (Fig. 2E), the stimulatory
effect of TOB on the deadenylation of BBB mRNA is likely to
be synergistic.
As a test of the generality of TOB’s enhancing effect on
deadenylation, the deadenylation kinetics of 	-globin mRNA
bearing a nonsense codon (BBBPTC) in the second exon
known to induce nonsense-mediated mRNA decay (3, 14)
were monitored in cells overexpressing TOB protein or coex-
pressing TOB and CCR4 (Fig. 2C and D). The results showed
that TOB also enhances deadenylation of BBBPTC mRNA
(Fig. 2C, middle panel; see also Fig. S1C, left, in the supple-
mental material). Coexpression of TOB and CCR4 caused
FIG. 1. Interactions between PABPC1, poly(A) nucleases, and
TOB. (A) GST pull-down assays examining the interactions between
PABPC1 and poly(A) nucleases. In vitro-translated and [35S]methi-
onine-labeled human CCR4, CAF1, PAN2, and PAN3 (top panel)
were incubated with MagneGST particle-immobilized GST-PABPC1,
and the resulting complexes were resolved by SDS-PAGE followed by
Coomassie blue staining (bottom panel) for equal bait loading and
then autoradiography (middle panel). PABPC1 and Paip2 were used
as positive controls, whereas luciferase (Luc) was used as a negative
control. (B) CCR4, CAF1, and TOB (top panel) were in vitro trans-
lated, [35S]methionine labeled, and incubated in combinations with
MagneGST particle-immobilized GST-PABPC1. GST pull-down (bot-
tom panel) was performed as described for panel A. Luciferase was
used as a negative control.
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FIG. 2. PABP-dependent enhancement of deadenylation by TOB. (A to D) Northern blots showing deadenylation and decay of the 	-globin
(BBB) (A and B) or BBBPTC (D and D) mRNA in the absence (vector) or presence of ectopically expressed wild-type TOB, mutant TOB(FF),
CCR4 and wild-type TOB, or CCR4 and mutant TOB(FF). NIH 3T3 B2A2 cells were transiently cotransfected with the reporter plasmid pTetBBB
(A and B) or pTetBBB-PTC (C and D), together with a control plasmid (pSV-globin/GAPDH) and plasmid(s) encoding wild-type TOB,
TOB(FF) mutant, CCR4, their combination, or an empty vector, as indicated underneath each panel. The -globin/GAPDH mRNA was expressed
constitutively and served as an internal standard for transfection efficiency and sample handling. The times given at the top correspond to hours
after tetracycline addition. Poly(A) RNA was prepared in vitro by treating the RNA sample from an early time point with oligo(dT) and RNase
H. (E) Western blot analysis of total lysates, showing that ectopically expressed TOB-V5 and HA-CCR4 can be readily detected by anti-V5 or
anti-HA antibody and that wild-type and mutant TOB proteins are expressed to a similar level. (F) Deadenylation profiles were drawn on the basis
of raw data collected from the corresponding Northern blots in panels A to D. For each panel (A to D), the profile for wild-type TOB (red) was
superimposed on that for mutant TOB (green) to illustrate the difference in deadenylation kinetics.
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even more rapid deadenylation (Fig. 2D, middle panel; see
also Fig. S1D, left, in the supplemental material). Moreover,
TOB2, a paralog of TOB, also exhibited a similar enhancing
effect on the deadenylation of both BBB and BBBPTC
mRNAs (see Fig. S2 in the supplemental material). This en-
hancing effect was further illustrated by subjecting the 	-globin
mRNA samples to oligonucleotide-directed RNase H cleavage
prior to Northern blotting (see Fig. S3 in the supplemental
material), which displayed a better resolution as the 3 frag-
ment of the message was shortened by 280 nucleotides.
To further substantiate the above conclusion, we also exam-
ined the effect of TOB overexpression on the poly(A) size
distribution of BBB mRNA when the message was constitu-
tively transcribed in NIH 3T3 cells under stationary or starva-
tion conditions (see Fig. S4 in the supplemental material).
Consistent with TOB proteins enhancing deadenylation, the
distribution of the BBB mRNA shifted toward a smaller size
when TOB proteins were overexpressed. Collectively, we con-
clude that TOB proteins can function as positive regulators of
deadenylation in vivo.
TOB can form a complex with poly(A)-PABP via interaction
with PABPC1. Interactions with cytoplasmic PABP have been
shown to be critical for PABP-interacting proteins to exert
their functions in translation and mRNA turnover (9, 27, 37).
To test whether the binding of TOB to PABPC1 is important
for its function in enhancing deadenylation, we first investi-
gated the interaction between TOB and poly(A)-PABP with
gel mobility shift assays. GST fused to PABPC1 (GST-
PABPC1) or to the first RNA recognition motif of PABPC1
(GST-PABP-RRM1) was expressed in E. coli. These fusion
proteins were then purified and incubated with a labeled 25-
mer poly(A) sequence to permit complex formation (Fig. 3,
lanes 2 and 6). Addition of purified TOB fused to maltose-
binding protein (MBP-TOB) caused a dramatic supershift of
the poly(A)-PABP complex, which resulted in an increase of
the poly(A)-PABP-TOB complex near the wells and a concom-
itant reduction of the poly(A)-PABP complex (Fig. 3, lanes 7
and 8). By contrast, there was only a very modest supershift of
poly(A)-PABP-RRM1 by TOB (Fig. 3, compare lanes 2 and 3
and lanes 3 and 8). Moreover, TOB itself did not form a
complex with the poly(A) sequence (Fig. 3, lanes 4 and 5).
Together, these results indicate that TOB can form a complex
with poly(A)-PABP via TOB’s interaction with PABPC1, sug-
gesting that binding to PABPC1 is important to the function of
TOB in enhancing deadenylation. These findings rule out the
possibility that TOB enhances deadenylation by destabilizing
the poly(A)-PABP complex.
F567 in the PABC domain of PABPC1 is critical for TOB
binding. To examine whether the physical interaction between
TOB and PABPC1 is important for enhancement of deadenyl-
ation, we set out to identify the binding sites on each protein
and test the effects of mutations that eliminate the interaction
on deadenylation. We first characterized the TOB-interacting
site(s) on PABPC1. Previously, we had shown that a C-termi-
nal sequence motif (PABC) (31) in the second half of the
PABPC1 C-terminal domain, previously known as PABP-C2
(9) and now referred to as PABP-2nd-C to avoid confusion
with the nomenclature for the mammalian PABPC1, contains
the TOB-binding domain (34). The phenylalanine at position
567 (F567) (Fig. 4A) of human PABPC1 was identified as a
critical residue for the interaction between the PABC motif
and two other PABP-interacting proteins, Paip-1 and Paip-2
(31). Accordingly, we introduced the single point mutation
F567A into GST-PABPC1 and GST-PABP-2nd-C and exam-
ined the effect on interaction with TOB. The F567A mutation
in the PABC motif effectively decreased the ability of PABPC1
and PABP-2nd-C to interact with TOB proteins (Fig. 4B). In
contrast, PABPC1 itself remained able to interact with the
mutant PABPC1 but not with wild-type PABP-2nd-C, since the
PABPC1-PABPC1-interacting domain was on the first half of
the C-terminal domain (40). Intriguingly, this mutation ap-
peared to enhance the PABPC1-PABPC1 interaction. An ad-
ditional control was further provided by showing that both
GST-PABPC1 and its F567A mutant, but not the PABP-2nd-C
nor its mutant, could pull down Paip2, consistent with a pre-
vious report (28) that PABPC1 has a strong Paip2-binding site
in the N-terminal RRM-containing domain. Taken together,
our data show that PABPC1 associates with the TOB proteins
via the PABC motif and that F567 in that motif is critical to the
interaction.
Highly conserved phenylalanines in the PAM2 motifs of
TOB are critical for its interaction with PABPC1. A consensus
PABC recognition site, termed PABP-interacting motif 2
(PAM2) (2), has been used to identify PABP-binding partners,
and one highly conserved phenylalanine residue in PAM2 has
been found to be critical for interaction with PABC (30). TOB
and TOB2 each contain two potential PAM2 motifs in their
C-terminal domains (Fig. 5A). We mutated the two conserved
phenylalanine residues in the potential PAM2 motifs of both
TOB proteins to alanine, namely, F139A and F274A in TOB
FIG. 3. TOB can form a complex with PABP-poly(A). A gel mo-
bility shift assay was carried out to determine TOB’s effect on
PABPC1-poly(A) complex formation. 32P-labeled poly(A)25 RNA was
incubated at room temperature alone (lane 1), with 0.68 pmol of
purified GST-PABP-RRM1 (lanes 2 and 3), or with 0.25 pmol of
purified GST-PABPC1 (lanes 6 and 7), followed by the addition of a
molar excess of MBP-TOB2 (1.7 pmol for lanes 3 and 6 and 6.8 pmol
for lane 7) as indicated. As a control, the probe was also incubated with
MBP-TOB2 alone (1.7 pmol for lane 4 and 6.8 pmol for lane 5). The
two arrowheads denote signals for complexes containing poly(A)-
PABP and poly(A)-PABP-TOB.
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and F140A and F260A in TOB2, to create TOB(FF) and
TOB2(FF). GST pull-down experiments (Fig. 5B) showed that
these double mutations effectively diminish the ability of both
TOB proteins to interact with PABPC1, via its PABC domain.
These results demonstrate that the highly conserved phenyl-
alanine residues in the PAM2 motifs of TOB are critical for
PABP binding.
In vivo interaction of TOB with PABPC1 and CCR4-CAF1.
To further substantiate the above GST pull-down data, coimmu-
noprecipitation and Western blotting experiments were per-
formed to address the in vivo association of TOB proteins with
both PABPC1 and CCR4-CAF1. In these experiments, TOB
proteins tagged with the V5 epitope were expressed in transfected
COS7 cells and immunoprecipitated by anti-V5 antibody (Fig.
6A). Consistent with the GST pull-down results, both wild-type
TOB and TOB2 proteins could pull down endogenous PABPC1,
whereas TOB proteins with mutated PAM2 motifs were largely
unable to pull down endogenous PABPC1. Endogenous CAF1
was coimmunoprecipitated readily with both TOB proteins, with
or without the PAM2 mutations, whereas PAN2 poly(A) nuclease
was not pulled down by TOB proteins (Fig. 6A). Due to the lack
of a strong antibody against endogenous CCR4, coimmunopre-
cipitation of CCR4 with TOB proteins was carried out using
HA-tagged CCR4 (Fig. 6B). The results show that TOB proteins,
wild type or mutant, pulled down only a modest amount of HA-
CCR4 (Fig. 6B). No CCR4 pull-down could be seen in the control
(Fig. 6B, right panel). Also, no GAPDH could be detected in the
precipitates (Fig. 6A and B, GAPDH control). These results
indicate that either a weak or an indirect interaction occurs be-
tween TOB proteins and CCR4, perhaps mediated by CAF1.
Taken together, these data confirm our in vitro experiments that
identified the TOB-PABPC1 interaction sites on both TOB pro-
teins (Fig. 5) and PABPC1 (Fig. 4). They further demonstrate
that CCR4-CAF1 and PABPC1 interact with the TOB proteins at
different sites, allowing the TOB proteins to associate simulta-
neously with both of them (Fig. 1B). These findings demonstrate
that an mRNP complex can be formed between TOB, poly(A)
nucleases, and poly(A)-PABP in mammalian cells.
FIG. 4. F567 in the PABC domain of PABPC1 is important for interaction with TOB. (A) Schematic representation of human PABPC1. RRM,
RNA recognition motif; PABP-2nd-C, the second half of the PABPC1 C-terminal domain, previously known as PABP-C2; PABC, poly(A)-binding
protein C-terminal motif. Phenylalanine (F) at position 567 is indicated with an asterisk and was mutated to alanine to create the PABPC1(F) or
PABP-2nd-C(F) mutant. (B) GST pull-down assay examining the TOB-binding region in PABPC1. In vitro-translated and [35S]methionine-labeled
TOB, TOB2, PABPC1, and Paip2 (left panel) were incubated with MagneGST particle-immobilized GST-PABPC1, GST-PABPC1(F), GST-
PABP-2nd-C, and GST-PABP-2nd-C(F) (top panel). GST pull-down was performed as described for Fig. 1.
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Interaction of TOB proteins with PABPC1 is critical for
enhancement of deadenylation. To assess whether PABP bind-
ing is important to TOB’s enhancement of deadenylation, we
examined the effect of the TOB(FF) double mutant, which
cannot bind PABPC1 effectively (Fig. 5B and 6A), on the
deadenylation of BBB or BBBPTC mRNA. The results (Fig.
2A, C, and F; see also Fig. S1A and C in the supplemental
material) showed that in contrast to the wild type, the TOB(FF)
mutant does not accelerate the deadenylation kinetics of either
BBB mRNA or BBBPTC mRNA. These results indicate that
the deadenylation-stimulatory function of TOB requires its inter-
action with PABPC1.
The above results were further corroborated by examining
the deadenylation of BBB and BBBPTC mRNA when the
TOB(FF) mutant was ectopically coexpressed with CCR4,
which is involved in the second phase of deadenylation of
mRNA (61). Overexpression of wild-type TOB with CCR4
further enhanced the second phase of deadenylation (Fig. 2B
and D, middle panel; see also Fig. S1B and D, left sides, in the
supplemental material). In contrast, overexpression of the
TOB(FF) double mutant slowed CCR4-mediated deadenyl-
ation (Fig. 2B and D [compare the later time points in the right
and left panels] and F, deadenylation profiles; see also Fig. S1B
and D in the supplemental material). Taken together, we con-
clude that TOB proteins enhance deadenylation in a PABP-
dependent manner.
TOB proteins colocalize with P-bodies in NIH 3T3 cells.
Recently, we have shown that decapping of mRNA does not
occur until the second phase of deadenylation, a step that
involves CCR4 (61), is under way. This step is stimulated by
TOB proteins, as shown from the results described above. It is
well established that shortening of the 3 poly(A) tail is closely
related to the movement of mRNPs from the translated pool to
the nontranslated pool, which may facilitate the entry of
mRNPs into P-bodies or to nucleate P-body formation. Ac-
cordingly, we examined the subcellular distribution of TOB in
relation to P-bodies. Green fluorescent protein (GFP) fusion
of DCP1a, a P-body component necessary for mRNA decap-
ping (5, 18, 32, 36, 54), has been widely used as a marker to
visualize P-body foci (15). In the cytoplasm of proliferating
NIH 3T3 cells, GFP-DCP1a was distributed in a focal pattern
(see Fig. S5A, upper panels, in the supplemental material). As
expected for P-bodies (17), the cytoplasmic foci marked by
FIG. 5. PABP binds PAM2 motifs in TOB. (A) Schematic repre-
sentations of human TOB and TOB2, showing PAM2. Phenylalanines
(F) at positions 139 and 274 in TOB as well as positions 140 and 260
in TOB2 are indicated with asterisks and were mutated to alanines to
create the TOB(FF) or TOB2(FF) mutants (mut). (B) GST pull-down
assay examining PABPC1-binding sites in TOB proteins. In vitro-
translated and [35S]methionine-labeled TOB, TOB(FF), TOB2, and
TOB2(FF) (left panel) were incubated with MagneGST particle-im-
mobilized GST-PABP and GST-PABC (top panel). GST pull-down
was performed as described for Fig. 1.
FIG. 6. Interactions between TOB proteins, PABPC1, and
poly(A) nucleases. COS7 cells were transfected with plasmids expressing
V5-tagged TOB, TOB(FF) mutant, TOB2, TOB2(FF) mutant, or
pcDNA6-V5 (as control) (A) or along with plasmid expressing HA-tagged
CCR4 (B). RNase A-treated cell extracts were first subjected to immu-
noprecipitation using anti-V5 antibody conjugated to agarose beads. Im-
munoprecipitates were then separated by SDS-PAGE and analyzed by
Western blotting using various antibodies as indicated to the left. The
molecular masses of each protein detected are indicated to the right. In
both panels, 5% of total lysate used for immunoprecipitation was included
as an input, for comparison.
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GFP-DCP1a disappeared after cycloheximide treatment (see
Fig. S5A, lower panels, and S5B, upper panels, in the supple-
mental material). Moreover, real-time imaging of live cells
showed that upon removal of cycloheximide, GFP-DCP1a foci
reappeared in the cytoplasm (see Fig. S5B, lower panels, in the
supplemental material), further validating GFP-DCP1a as a
P-body marker in NIH 3T3 cells.
Immunoblotting has detected endogenous TOB in NIH 3T3
cells in the G0/G1 phase (25, 49), but anti-TOB antibodies
suitable for immunofluorescence microscopy are currently un-
available. Therefore, we used V5 epitope-tagged TOB2 pro-
tein (TOB2-V5) expressed in transfected NIH 3T3 cells to
examine the subcellular distribution of TOB protein. CENP-F,
a centromere protein present at peak levels in the nuclear
matrix in the G2 and M phases (33), was used to distinguish
cells in G2 and M phases from those in G1 and S phases. Figure
7 shows that TOB2-V5 colocalizes with P-bodies in cells with
little or no nuclear staining of CENP-F, whereas no obvious
TOB-V5 foci could be detected in cells with strong nuclear
staining of CENP-F, although P-bodies were still visible in
those cells. Taken together, these results indicate that TOB
colocalizes with P-bodies in NIH 3T3 cells in a manner corre-
lating with its cell-cycle-regulated expression.
DISCUSSION
The poly(A) nucleases involved in deadenylation of mRNA
in various organisms have started to be identified and charac-
terized in the last decade. The CCR4-CAF1 complex accounts
for the major deadenylation activity in Saccharomyces cerevi-
siae and Drosophila melanogaster (50, 51). In mammals, a sec-
ond poly(A) nuclease complex, PAN2-PAN3, has recently
been shown to initiate deadenylation prior to CCR4-CAF1
action (61). Given that deadenylation of mRNA has the im-
portant consequence of shutting off translation of the tran-
script, a void in our understanding of how deadenylation is
controlled, particularly in mammalian somatic cells during
mRNA turnover, has prompted us to examine the underlying
mechanisms.
Previous studies (29, 41, 53, 61) suggested that communica-
tion between poly(A) nuclease complexes PAN2-PAN3 and
CCR4-CAF1 and the 3 PABP-poly(A) tail complex of the
mRNA in mammalian cells can greatly influence the poly(A)
nuclease activity and, thus, the rate and extent of deadenyla-
tion. In this study, we set out to identify protein factors that
mediate or modulate the interaction between the CCR4-CAF1
complex and the PABP-poly(A) complex. Our results led to
three main findings. First, TOB, previously considered a tran-
scription factor, can function as a positive, PABP-dependent
regulatory factor in the deadenylation of both wild-type stable
and nonsense-containing unstable 	-globin mRNAs. Second,
TOB can associate simultaneously with cytoplasmic PABP
via TOB’s C-terminal PAM2 motifs and with CAF1 through
TOB’s N-terminal domain. Third, TOB colocalizes with P-
bodies in the G1 phase but not in the G2 or M phase.
Although it was previously reported that TOB can separately
interact with CAF1 (25) and bind PABP (25, 43), those studies
did not determine whether TOB can simultaneously interact
with both PABP and CAF1. Moreover, the functional signifi-
cance of these interactions for regulating deadenylation re-
mains unclear. The present results (Fig. 2 and 6) not only
demonstrate a direct interaction between TOB and PABPC1
but also reveal that the PAM2 motifs in TOB and the PABC
FIG. 7. TOB2 colocalizes with P-bodies in a cell-cycle-related manner. Immunofluorescence microscopy experiment results show the subcel-
lular distributions of V5-TOB2 and P-bodies marked by GFP-DCP1a in proliferating mouse NIH 3T3 cells. V5-TOB2 was visualized using primary
mouse anti-V5 antibody followed by secondary goat anti-mouse Alexa 555 antibody. To distinguish cells in G2 and M phases from cells in G1 and
S phases, cells were stained for a centromere marker protein, CENP-F, by the rabbit primary antiserum against CENP-F and donkey anti-rabbit
Alexa 647 antibody. Cell nuclei were detected by DAPI staining.
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motif in PABPC1 are necessary for the interaction, thus estab-
lishing TOB as a genuine PABP-interacting protein.
Our observation of an enhancing effect of TOB on deadeny-
lation raises an important question as to whether TOB directly
destabilizes the poly(A)-PABP complex. In a gel mobility shift
assay, we showed that while TOB does supershift the PABP-
poly(A) complex, it has little effect on the complex formed
between poly(A) and a truncated PABP that contains only the
first RNA-binding domain (Fig. 3). These results suggest that
instead of destabilizing the poly(A)-PABP complex, TOB pro-
motes deadenylation through its interaction with the poly(A)-
PABP complex, possibly by recruiting poly(A) nucleases, such
as CCR4-CAF1, to the 3 poly(A) tail and/or by modulating
their poly(A) nuclease activity. It is of particular interest that
TOB’s deadenylation-enhancing effect is dependent on its in-
teraction with PABP (Fig. 2; see also Fig. S1 in the supple-
mental material). When a double point mutation was intro-
duced into the two PAM2 motifs in TOB proteins, their ability
to interact with PABPC1 was greatly diminished. This finding
is consistent with the above notions.
The ability of TOB to modulate deadenylation via the
CCR4-CAF1 complex is reminiscent of the actions of yeast
PUF proteins, a family of RNA-binding proteins that inter-
act with the 3 untranslated regions of specific mRNAs and
stimulate their deadenylation (57). One of the yeast PUF
proteins, Mpt5p, has been shown to physically bind Pop2p,
a homolog of mammalian CAF1 (21, 22). By binding Pop2p,
Mpt5p recruits the cytoplasmic Ccr4p-Pop2p deadenylase
complex to the target transcript, thus promoting removal of
its poly(A) tails and consequent repression of its translation.
Thus, it appears that both mammalian TOB and yeast
Mpt5p proteins regulate mRNA decay through recruiting
the CCR4-CAF1 complex to stimulate deadenylation. Yet,
there are distinct differences between the yeast and mam-
malian systems. Whereas the PUF proteins act in an RNA
sequence-specific manner, TOB proteins interact with the
PABPC1 protein of the 3 poly(A)-PABP complex and thus
are likely to function in an RNA sequence-independent way.
Another difference is that there is no known TOB ortholog
in yeast, but the interaction between PUF and POP2 is
conserved in yeast, Drosophila, and humans (24, 39). More-
over, TOB belongs to a family of antiproliferative proteins
whose levels of expression change during the cell cycle,
while expression of PUF proteins is not known to be related
to the cell cycle. Thus, two distinct families of unrelated
proteins, TOB and PUF, that share no homology and play
different roles in embryogenesis, cell growth, and cell dif-
ferentiation appear to have evolved independently to ac-
complish their functions by converging on deadenylation.
What may be the biological significance or consequence of
enhanced deadenylation by TOB? Our experiments show that
TOB enhances deadenylation without significantly changing
the overall decay rate of the deadenylated RNA body. Several
observations in this and other studies suggest a role for the
TOB proteins in facilitating the exit of mRNPs from the trans-
lation pool to the nontranslated pool residing in P-bodies.
First, the enhancement of deadenylation observed with TOB
could help to stop translation initiation by abolishing the in-
teraction between the 5 cap and the 3 poly(A) tail. Second,
TOB interacts with the C-terminal PABC domain of PABP, a
region that is also used during translation for interactions with
Paip1, Paip2, eukaryotic initiation factor 4B, eRF3, and the
60S ribosomal subunit (2). One might imagine that TOB could
compete with these factors and thus decrease translation effi-
ciency. The above notions are consistent with the role for TOB
in translation repression implicated in a recent report that
overexpression of TOB in an NIH 3T3 cell line, stably express-
ing exogenous inducible PABP, results in reduction of inter-
leukin-2 protein expression from a simultaneously transfected
interleukin-2 plasmid (43). Third, TOB colocalizes in the G1
phase with P-bodies, structures linked to silencing translation
and/or for storing translationally repressed mRNPs (for a re-
cent review, see reference 17). One possibility is that after
promoting deadenylation, TOB may facilitate remodeling of
mRNPs and their movement into P-bodies, thus repressing
translation.
In summary, our data suggest that TOB provides func-
tional links among deadenylation, P-bodies, and cell growth
arrest. Consistent with this notion is a study that showed
that overexpression of CAF1 leads to cell growth arrest (7).
It will be interesting to learn how knockdown of TOB ex-
pression may change the mRNA expression profile in cells
arrested in the G0/G1 phase. The information gathered has
the potential to provide important insight into TOB’s func-
tion as an antiproliferative factor. Given that phosphoryla-
tion of TOB at specific serines inactivates its antiprolifera-
tive function when cells exit the G0/G1 phase (49), it will also
be important to address whether and how those posttrans-
lational modifications may regulate TOB’s function in mod-
ulating deadenylation.
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